



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2774335 C 2016/10/18

(11)(21) **2 774 335**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) **Date de dépôt PCT/PCT Filing Date:** 2010/09/16
(87) **Date publication PCT/PCT Publication Date:** 2011/03/24
(45) **Date de délivrance/Issue Date:** 2016/10/18
(85) **Entrée phase nationale/National Entry:** 2012/03/15
(86) **N° demande PCT/PCT Application No.:** SE 2010/050996
(87) **N° publication PCT/PCT Publication No.:** 2011/034495
(30) **Priorité/Priority:** 2009/09/16 (US61/272,351)

(51) **Cl.Int./Int.Cl. A61K 39/106** (2006.01),
A61K 39/108 (2006.01)
(72) **Inventeurs/Inventors:**
HOLMGREN, JAN, SE;
LEBENS, MICHAEL, SE
(73) **Propriétaire/Owner:**
MSD WELLCOME TRUST HILLEMANN LABORATORIES
PVT LTD., IN
(74) **Agent:** BORDEN LADNER GERVAIS LLP

(54) **Titre : VACCIN CONTRE LA DIARRHÉE DUE AU CHOLERA ET A E. COLI ENTEROTOXIGÈNE (ETEC)**
(54) **Title: VACCINE AGAINST CHOLERA AND ENTEROTOXIGENIC E. COLI (ETEC) DIARRHEA**

(57) **Abrégé/Abstract:**

A vaccine against cholera and/or ETEC is provided, comprising a *Vibrio cholerae* O1 cell, characterized in that said cell comprises O1 antigens of both Ogawa and Inaba serotypes. Genetically modified *Vibrio cholerae* O1 cells for use in such vaccines, DNA-constructs for the modification, uses for the vaccine and methods of making a vaccine are also provided.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 March 2011 (24.03.2011)

PCT

(10) International Publication Number
WO 2011/034495 A1

(51) International Patent Classification:

A61K 39/106 (2006.01) **A61K 39/108** (2006.01)

(21) International Application Number:

PCT/SE2010/050996

(22) International Filing Date:

16 September 2010 (16.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/272,351 16 September 2009 (16.09.2009) US

(71) **Applicant** (for all designated States except US): **GOTO-VAX AB** [SE/SE]; Korvettgatan 1D, S-426 74 Västra Frölunda (SE).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **HOLMGREN, Jan** [SE/SE]; Korvettgatan 1D, S-426 74 Västra Frölunda (SE). **LEBENS, Michael** [SE/SE]; Dannarp 103, S-523 99 Hökerum (SE).

(74) **Agent:** **ALBIHNS.ZACCO AB**; P.O. Box 5581, Valhallavägen 117, S-114 85 Stockholm (SE).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) **Title:** VACCINE AGAINST CHOLERA AND ENTEROTOXIGENIC E. COLI (ETEC) DIARRHEA

(57) **Abstract:** A vaccine against cholera and/or ETEC is provided, comprising a *Vibrio cholerae* O1 cell, characterized in that said cell comprises O1 antigens of both Ogawa and Inaba serotypes. Genetically modified *Vibrio cholerae* O1 cells for use in such vaccines, DNA-constructs for the modification, uses for the vaccine and methods of making a vaccine are also provided.



WO 2011/034495 A1

Vaccine against cholera and enterotoxigenic *E. coli* (ETEC) diarrhea

Technical field the invention

The present invention relates to the field of vaccines, in particular vaccines against
5 cholera and enterotoxigenic *E. coli* (ETEC) diarrhea.

Background to the invention

Cholera remains a major health problem in large parts of the world. This is also true
for ETEC, which is the main cause of diarrheal disease in developing countries as well
as in travelers to these countries. In many developing countries effective water and
10 sanitary measures for control of cholera and other enteric infections are currently
impossible, and in this context, vaccines have an important role to play. In order to
do so however, they need to be effective, readily accessible and above all cheap.
There is also a medical need and a very substantial commercial market for use of
cholera and especially ETEC vaccines in travelers.

15 One approach has been the development of oral killed whole cell vaccines. Dukoral[™]
is an oral cell vaccine (OCV) with demonstrated up to 90% efficacy against cholera
and also a significant efficacy against Enterotoxigenic *Escherichia coli* (ETEC)-induced
diarrhea. It comprises 3 different *V. cholerae* strains in four different formulations
(two heat-killed and two formalin-killed) and in addition recombinantly produced
20 cholera toxin B subunit (rCTB). The rCTB component contributes significantly to the
efficacy against cholera and is solely responsible for the observed protection against
ETEC diarrhea due to its ability to induce cross-neutralizing antibodies against the
cholera toxin (CT)-like *E. coli* heat-labile toxin (LT). However, rCTB is acid-labile and
thus the vaccine (which needs to be given in two doses) must be administered with a
25 bicarbonate buffer.

Despite Dukoral[™] being the only internationally licensed OCV, copies of this vaccine
with or without the CTB component are currently being marketed in developing

countries – Vietnam, India and China. The OCV made in Vietnam and India (which lacks the CTB component) contains the same 4 bacterial components as in Dukoral plus a fifth formalin-killed *V. cholerae* strain of serogroup O139.

Protective immunity against cholera elicited by OCVs is mainly if not exclusively based on mucosal production of antibodies against cell wall lipopolysaccharide O1 (O1 LPS) and for the CTB-containing Dukoral vaccine also antitoxin antibodies in the intestine.

From the above it is evident that the present state of the art for production of cholera/ETEC vaccine is far from simple, and although already effective, a real contribution to making a cholera vaccine more accessible would be to rationalize the composition of the formulation at several levels.

The necessity to include several different *Vibrio cholerae* strains in killed whole cell vaccines such as Dukoral™ arises from the need to represent several different antigenic variants of *Vibrio cholerae* in the vaccine. All protective strains in the currently used vaccines are of the O1 serogroup which until 1993 was the only one of more than 200 identified serogroups known to cause epidemic cholera and is still the dominant serogroup. However, the O1 serogroup has two variants called the Ogawa and Inaba serotypes that differ in the methylation of the terminal sugar of the O-antigen of the surface lipopolysaccharide (LPS). Serotype switching is known to occur in which the Ogawa serotype organism can give rise to Inaba organisms. The reverse switch however is rare.

Although immunization with especially Inaba but also Ogawa serotype can give rise to antibodies cross-reacting with the other serotypes it also gives rise to serotype specific antibodies that contribute significantly to protection. Thus, an effective vaccine should induce not only cross reactive but also serotype-specific antibodies against both Inaba and Ogawa serotype variants.

The serotype switch is known to be related to a mutation in a single gene (*wbeT*). Any mutation that inactivates this gene results in a switch from the Ogawa to the Inaba serotype. Mutations that can reverse such an event are predictably much more

uncommon although a switch from the Inaba to the Ogawa serotype can easily be achieved by provision of the relevant gene *in trans*. The gene involved (*wbeT*, also denoted *rfbT*) encodes a methyl transferase that methylates the terminal perosamine residue in the O-antigen polysaccharide repeating unit. Mutations in this gene that lead to the Inaba serotype are almost invariably insertions, deletions or base changes that introduce a nonsense codon.

A third O1 variant known as Hikojima has also been documented to occur in the wild. Hikojima is characterized by that it expresses both the Ogawa and Inaba determinants on its surface and agglutinates with antisera specific for both types. The Hikojima phenotype is extremely rare and is considered in the literature to be an unstable transitional form.

With this in mind the inventors have set out to engineer a single vaccine strain of *V. cholerae* that would effectively replace the three currently used strains.

Thus, it is an object of the invention to provide an efficient vaccine against cholera and/or ETEC diarrhea, with simplified formulation and with lower productions costs and that also ideally produces protective immunity after single administration.

Summary of the invention

The present invention describes the construction, method of manufacture, formulation and medical-preventive use of a novel cholera and/or ETEC vaccine.

Throughout this text, in line with established scientific practice, the designation “*wbeT*” (in italics) denotes the **gene**, whereas the designation “*WbeT*” (in italics) denotes a **protein** coded for by a *wbeT* gene.

In a **first aspect**, a vaccine comprising a *Vibrio cholerae* O1 cell, characterized in that said cell comprises O1 antigens of both Ogawa and Inaba serotypes is provided.

The vaccine may comprise multiple *Vibrio cholerae* O1 cells that comprise O1 antigens of both Ogawa and Inaba serotypes, and wherein on average, 10-90 % of the O1 antigens of said cells are of the Ogawa-serotype.

Preferably, 10-90 % of the O1 antigen expressed by the cells is of the Ogawa-serotype. More preferably, 10-70 % of the O1 antigen expressed by the cells is of the Ogawa-serotype. Yet more preferably, 10-50 % of the O1 antigen expressed by the cells is of the Ogawa-serotype. Still more preferably, 10-40 % of the O1 antigen expressed by the cells is of the Ogawa-serotype. Most preferably, 10-30 % of the O1 antigen expressed by the cells is of the Ogawa-serotype.

10 The cell of the vaccine may further comprise one or more ETEC colonization factor (CF) protein(s), such as CFA/I, CS2 or CS5, wherein said CF protein(s) is/are expressed either as single, double or hybrid fimbriae.

Preferably, said vaccine does not contain any further immunologically active whole cells in addition to *Vibrio cholerae* O1 cells that comprise O1 antigens of both Ogawa
15 and Inaba serotypes.

Preferably, the vaccine is for oral administration. Preferably, the cell in the vaccine is formalin-inactivated.

Preferably, the cell is a genetically modified cell, preferably a genetically modified cell according the seventh or eighth aspects of the invention (see below).

20 In a **second aspect** a vaccine according to the first aspect is provided, for use in preventive immunization, preferably for use in preventive immunization against cholera and/or enterotoxigenic *Escherichia coli*-infection (ETEC).

In a **third aspect**, a method for inducing preventive immunity is provided, comprising administering a vaccine according to the first aspect to a subject to be immunized.

25 Preferably, the preventive immunity is against cholera and/or enterotoxigenic *Escherichia coli*-infection (ETEC). Also preferably, the the administration is done orally.

In a **fourth aspect**, a DNA-construct is provided, comprising DNA coding for a *WbeT*-protein having at least 70 % sequence identity to SEQ ID NO: 6 (more preferably at least 80 % identity, even more preferably at least 90 % identity, yet more preferably at least 95 % identity and most preferably at least 99 % identity) operatively coupled
5 to a promoter suitable for inducing protein expression in a *Vibrio cholerae* O1 host cell, characterized in that the coded *WbeT*-protein comprises sequence modifications in relation to SEQ ID NO: 6 that reduce the enzymatic activity of the coded protein relative to the enzymatic activity of a protein with a sequence identical to SEQ ID NO: 6.

10 Preferably, the sequence modifications comprise a substitution of the serine residue in position 158 of SEQ ID NO: 6, more preferably a substitution of the serine residue in position 158 of SEQ ID NO: 6 to glycine, proline, threonine, phenylalanine or tryptophan.

In a **fifth aspect**, a DNA-construct is provided, comprising DNA coding for a *WbeT*-
15 protein having at least 70 % sequence identity to SEQ ID NO: 6 (more preferably at least 80 % identity, even more preferably at least 90 % identity, yet more preferably at least 95 % identity and most preferably at least 99 % identity) operatively coupled to a promoter suitable for inducing protein expression in a *Vibrio cholerae* O1 host cell, characterized in that the promoter is suitable for inducing the expression of the
20 coded *WbeT*-protein in a *Vibrio cholerae* O1 host cell initially of Inaba phenotype (i.e. host cell which is Inaba prior to transformation by the DNA construct) to such level of transgenic *WbeT* protein expression as to allow simultaneous expression of both Inaba and Ogawa antigens by the host cell.

Preferably, the promoter of the above aspects is an inducible promoter, such as a *tac*
25 or *lac* promoter.

Preferably, the DNA construct of the above aspects is a plasmid vector capable of replication in a host cell or a vector capable of chromosomal integration in a host cell.

Preferably, the DNA-construct according to the above aspects further comprises a selectable marker, more preferably a positive selectable marker such as antibiotic resistance gene or a metabolic selectable marker.

In a **sixth aspect**, a DNA construct for homologous recombination in a *Vibrio Cholerae* O1 host is provided, characterized in that the construct is adapted to modifying the endogenous *wbeT* gene of the host by means of homologous recombination.

Preferably, the DNA-construct according to the sixth aspect further comprises a selectable marker, more preferably a positive selectable marker such as antibiotic resistance gene or a metabolic selectable marker.

In a **seventh aspect**, a *Vibrio cholerae* O1 cell simultaneously expressing both Inaba and Ogawa antigens is provided, characterized in that

- a. the endogenous *wbeT*-gene of the host cell or the protein coded thereof is inactive;
- b. the cell comprises a recombinant DNA-construct inducing expression of *WbeT* enzyme activity; and wherein
- c. the level of transgenic *WbeT* enzyme activity is such that the cell simultaneously expresses Inaba and Ogawa antigens.

Preferably, the recombinant DNA-construct of the above aspects is a DNA construct according to the fourth to fifth aspects.

In an **eighth aspect**, a *Vibrio cholerae* O1 cell simultaneously expressing both Inaba and Ogawa antigens is provided, characterized in that

- a. the cell comprises an endogenous *wbeT*-gene; and
- b. the cell comprises a recombinant DNA-construct capable of modulating the expression level of endogenous *wbeT* gene or the enzymatic activity of the product thereof; and wherein

- c. the modulated level of *WbeT* enzyme activity is such that the cell simultaneously expresses Inaba and Ogawa antigens.

Preferably, the recombinant DNA-construct of the above aspect is a DNA construct according to the sixth aspect.

- 5 Preferably, 10-90 % of the O1 antigen expressed by the cell of the above aspects is of the Ogawa-serotype. More preferably, 10-70 % of the O1 antigen expressed by the cell of the above aspects is of the Ogawa-serotype. Yet more preferably, 10-50 % of the O1 antigen expressed by the cell of the above aspects is of the Ogawa-serotype. Still more preferably, 10-40 % of the O1 antigen expressed by the cell of the above aspects is of the Ogawa-serotype. Most preferably, 10-30 % of the O1 antigen expressed by the cell of the above aspects is of the Ogawa-serotype.

Preferably, the cell of the above aspects further expresses one or more ETEC colonization factor (CF) protein(s), such as CFA/I, CS2 or CS5, wherein said CF protein(s) is/are expressed either as single, double or hybrid fimbriae.

- 15 In a **ninth aspect**, a method for manufacturing a vaccine is provided, comprising the steps of:

providing a *Vibrio cholerae* O1 cell comprising O1 antigens of both Ogawa and Inaba serotypes; and
killing said cell.

- 20 Preferably, the killing is performed by formalin-treatment or by heat-treatment.

Preferably, the cell is a cell according to the seventh or the eighth aspects.

In a **tenth aspect**, the invention also relates to a kit for use in vaccination formulated as a one-unit composition, whereby the composition is presented in one part of the kit and instructions for use in another part.

- 25 **Detailed description of the invention**

Vaccine comprising cells with O1 antigens of both Ogawa and Inaba serotypes

Although *V. cholerae* of serogroup O139 can also cause cholera, >98% of all cholera worldwide is caused by *V. cholerae* O1. The O1 serogroup has two subtypes/serotypes - Ogawa and Inaba. Serotype switching from the Ogawa to the Inaba subtype occurs at a relatively high frequency whereas the reciprocal conversion is rare. The basis of the serotype switch is a mutation in the LPS synthetic pathway that leads to change in the structure of the O1 antigen. An effective vaccine need to include both Ogawa and Inaba strains in its composition since their LPS are serologically distinct with both shared and distinct epitopes contributing to protection.

A vaccine comprising *Vibrio cholerae* O1 cells expressing O1 antigens of both Ogawa and Inaba serotypes is disclosed, and has the advantage of simplifying production because it obviates the need to use distinct cells for each of the phenotypes in the manufacture of the vaccine. By enabling the use of single type of cell, the manufacture of the vaccine is also simplified, since only one type of inactivation treatment is needed.

Immunization with vaccine of the invention based on single *V. cholerae* strain that express different amounts of both Ogawa and Inaba serotypes gives rise to cross-reactive as well as type-specific antibodies to both Ogawa and Inaba antigens (see example 1).

It is preferable that on average, 10-90 % of the O1 antigens of the cells are of the Ogawa-serotype. The Inaba-antigen is preferably present in a higher amount (meaning more than 50 %) than the Ogawa-antigen, as the Inaba-antigen can elicit a certain level of cross-serotype protection against Ogawa, whereas Ogawa-antigen can only elicit protection against itself.

The efficacy of the vaccine against ETEC may further be improved by incorporation of the feature that the cells further express one or more ETEC colonization factor (CF) protein(s), such as CFA/I, CS2 or CS5, wherein said CF protein(s) is/are expressed either as single, double or hybrid fimbriae (see below for details).

It is preferable, that the above vaccine does not contain any further immunologically active whole cells in addition to *Vibrio cholerae* O1 cells that comprise O1 antigens of both Ogawa and Inaba serotypes. However, the above vaccine may further comprise recombinant CTB in a manner similar to Dukoral™.

- 5 The vaccine is preferably for oral administration, but may also be administered by injection. Preferably, the vaccine comprises *Vibrio cholerae* O1 cells that comprise O1 antigens of both Ogawa and Inaba serotypes that are formalin-inactivated.

Preferably, the vaccine comprises genetically modified *Vibrio cholerae* O1 cells, preferably such genetically modified *Vibrio cholerae* O1 cells as described below.

- 10 The vaccine of the invention may be a vaccine composition comprising one or more pharmaceutically acceptable, excipients, carriers, diluents and adjuvants.

The formulation of vaccine compositions according to the invention is well known to persons skilled in the art. Suitable pharmaceutically acceptable carriers and/or diluents include any and all conventional solvents, dispersion media, fillers, solid carriers, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art, and is described, by way of example, in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent is
15
20 incompatible with the active ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

The vaccine composition for oral use may preferably comprise 10^8 - 10^{14} cells/ml, more preferably 10^{10} - 10^{12} cell per ml, and most preferably about 10^{11} cells/ml.

- 25 The vaccine composition for oral use may be formulated as a foodstuff, beverage or a feed supplement (when for use in immunizing animals).

The vaccine composition may comprise an adjuvant known in the art, or may lack any adjuvants.

Use of the vaccine

The present invention discloses use of the above vaccine in preventive immunization, preferably against cholera and/or enterotoxigenic *Escherichia coli*-infection (ETEC).

Preferably, the vaccine is administered orally or sublingually.

The present invention also discloses a method for inducing preventive immunity, comprising administering a vaccine according to the above to a subject to be immunized. Preferably, the preventive immunity is against cholera and/or

enterotoxigenic *Escherichia coli*-infection (ETEC). Preferably, the administration is done orally or sublingually. The administration may also be done by injection.

The vaccine is preferably used to immunize humans and other mammals, such as pets (cats, dogs and the like) or farm animals (such as cows, horses, sheep, goats, pigs and the like).

Preferably, the vaccine is administered orally at 10^8 - 10^{14} cells per dose, more preferably 10^{10} - 10^{12} cells per dose, and most preferably about 10^{11} cells per dose.

The immunization protocol may consist of a single administration or may comprise two or more administrations. In a preferred embodiment, the initial immunization protocol to induce protective immunity comprises a first administration and a second administration, separated in time by at least 7 days but by no more than about 2 months. After the initial immunization protocol, protective immunity may be maintained as long as desired by booster administrations occurring with less than 3 year intervals, preferably less than 2 year intervals. It may be preferable that a booster administration does not take place before at least 1 year has elapsed from the first administration.

Method of manufacture for a vaccine

A method for manufacturing a vaccine is disclosed, comprising the steps of:

- a. providing a *Vibrio cholerae* O1 cell comprising O1 antigens of both Ogawa and Inaba serotypes; and
- b. killing said cell, such as by formalin treatment or by heat treatment.

Preferably, the killing is performed by formalin-treatment. Preferably the cell is a
5 genetically modified cell, preferably such as described below.

Besides having the advantage enabling the use of a single inactivation (killing) method, the vaccine may be manufactured using standard protocols known e.g. from the manufacture of Dukoral™.

Genetically modified cells useful for vaccine manufacture and DNA constructs for 10 obtaining such cells

The *Vibrio cholerae* cells comprising O1 antigens of both Ogawa and Inaba serotypes comprised in the vaccine could in principle be obtained from a naturally occurring strain having a Hikojima phenotype. However, to the best knowledge of the inventors such strains are very rare and no such strains are presently available to the public. In
15 the literature, such natural strains have also been described as unstable, which renders them less promising for industrial production of vaccines.

Thus, the inventors have derived *V. cholerae* cells that express O1 antigens of both Ogawa and Inaba serotypes by way of genetic engineering and have obtained novel strains with stable Hikojima phenotype. Cells derived in this manner also have the
20 advantage that any desired strain (such as a known and well-characterized vaccine strain) can be used as a starting point, substantially simplifying the production and streamlining the experiments needed for GMP production and regulatory approval.

The inventors demonstrate herein that the key parameter for obtaining the desired Hikojima phenotype is to obtain a suitable level of *WbeT* enzyme activity. By suitable
25 in this context is meant that the *WbeT* enzyme activity level of the cell is not so low that the cells have an essentially pure Inaba phenotype and not so high that the cells have an essentially pure Ogawa phenotype.

In the context of the present invention, it is preferable that 10-90% of the O1 antigens on the cells are of the Ogawa type (with remainder consequently of the Inaba type). More preferably, 10-80% of the O1 antigens on the cells are of the Ogawa type, yet more preferably 10-50%, still more preferably 10-40% and most preferably 20-30%.

As shown in the Examples below, a suitable Hikojima phenotype as outlined above is obtainable by several distinct strategies utilizing recombinant DNA technology:

- a) A mutant *WbeT* protein having low enzymatic activity may be expressed at high levels in a host having Inaba phenotype;
- b) A *WbeT* protein having high enzymatic activity may be expressed at low levels in an Inaba host; or
- c) The endogenous *WbeT* gene of an Ogawa host may be mutated e.g. by means of homologous recombination to render the resulting protein to have suitably reduced activity.
- d) The endogenous *WbeT* gene of an Inaba host may be replaced or modified e.g. by means of homologous recombination to render the protein produced by the gene to have suitably increased activity.

The present invention discloses cells obtained by each of the above strategies, as well as DNA-constructs suitable for obtaining cells by each of the above strategies.

From the teachings herein it is apparent to the skilled person that achieving the desired level of *WbeT* expression by the strategies outlined above can be realized in many different ways. For instance, levels of expression of a *WbeT* transgene may be modulated by using an inducible promoter (such as *cat*, *lac* or *tac*) whereby the level of expression may be modulated during culture of the host cells by adjusting the level of the inducer that the host cells are exposed to.

Alternatively, several weak and strong constitutional promoters are also known and may be used in conjunction with a suitably modified *WbeT* protein. A weak promoter

can be used to constitutionally induce a very low level of expression of a highly active (such as wild-type; SEQ ID NO: 6) *WbeT* protein. Conversely, a strong constitutional promoter can be used to induce a high level of expression of a *WbeT* protein having low activity (such as a mutated *WbeT* protein, preferably such as described below).

- 5 Both plasmids and chromosomally integrated *wbeT* transgenes may be used in the cells of the invention to achieve the desired phenotype.

Many different mutations of the *WbeT*-protein can potentially result in a suitably active protein, and such mutated variants can readily be obtained by the skilled person using methods well known in the arts by mere routine experimentation, on
10 the basis of the teachings herein. Whether a cell of the desired phenotype is obtained by expressing the mutated *WbeT* protein or not can readily be analyzed by the skilled person e.g. using the methods disclosed in Example 5. The inventors have identified serine 158 in the *WbeT* protein (SEQ ID NO: 6) as a suitable residue to modulate activity. Thus, the mutations preferably comprise a substitution on serine 158, more
15 preferably substitution of serine 158 to glycine, proline, valine, leucine, alanine, threonine, methionine, tryptophan, arginine or phenylalanine. Most preferably, the serine 158 is substituted by glycine, proline, threonine, phenylalanine or tryptophan.

ETEC colonization factor (CF) protein(s)

As is evident from the above, the vaccine of the invention (or rather the cells on
20 which the vaccine is based upon) may also comprise other enhanced features besides the combined expression of O1 antigens of both Inaba and Ogawa serotypes. In particular, the cells may express one or more ETEC colonization factor (CF) proteins, such as CFA/I, CS2 or CS5, wherein said CF protein(s) is/are expressed either as single, double, or hybrid fimbriae, as demonstrated in Example 7. Inclusion of such CF
25 proteins in the cells of the vaccine is especially useful for inducing protective immunity against ETEC.

All references cited herein are hereby incorporated by reference in their entirety.

The expression "comprising" as used herein should be understood to include, but not be limited to, the stated items.

The invention is further illustrated by the following examples, which are to be seen as non-limiting.

5

Example 1. Preparation and testing of a vaccine comprising *Vibrio cholerae* cells comprising O1 antigens of both Ogawa and Inaba serotypes

It was tested whether a vaccine comprising *V. cholerae* bacteria of strain JS1569 (Inaba) that had been genetically modified to express O1 antigens of both Ogawa and Inaba serotypes would give rise to an antibody response with a different proportion of antibodies reacting with Ogawa and Inaba LPS in ELISA as compared to the antibody response after immunization with the parent JS1569 Inaba strain.

The bacteria from example 2 (see below) were formalin-killed and used for immunization. Formalin-killing of bacteria and oral immunizations and assay methods were performed as previously described (Nygren E, Li BL, Holmgren J, Attridge SR. Infect Immun. 2009 Aug;77(8):3475-84). Briefly, Balb/c mice were immunized in 3 rounds at 2-week intervals with two daily doses of 3×10^8 formalin-killed cells (together with an adjuvant for the WbeT strain), and one week after the last immunization the mice were sacrificed and serum collected and tested for combined IgG/IgM antibody titers in ELISA plates coated with either Inaba or Ogawa LPS.

The results are presented in the table below and show that in contrast to the parent JS1569 Inaba strain which gave rise to an antibody response with a slightly higher anti-Inaba than anti-Ogawa titer, the JS1569/wild type Wbe S158S vaccine gave rise to an antibody response with a much higher anti-Ogawa than anti-Inaba titer, although it still gave rise also to modest formation of specific anti-Inaba antibodies:

Immune serum	Inaba/Ogawa titers (Ratio)
To JS1569	10290/5060 (2:1)

Same absorbed with Ogawa	2940/160 (18:1)
To JS1569/ wild type Wbe S158S	36000/365000 (1:10)
Same absorbed with Inaba	1600/49000 (1:30)
Same absorbed with Ogawa	1700/2500 (1:1.5)

These findings were confirmed when immunizations were given subcutaneously without adjuvant. In marked difference to immunization with the parent JS1569 Inaba strain and more similar to immunization with the Ogawa A457 reference strain, immunization with JS1569 WbeT gave rise to immune serum with a strong proportion of Ogawa specific antibodies, as shown in the table below.

Immune serum	Inaba titer	Ogawa titer	Ratio Inaba/Ogawa
JS1569 Inaba	480	260	1.8:1
JS1569 abs with Ogawa A457	180	60	3:1
JS1569 abs with 1569 WbeT	240	60	4:1
A457 Ogawa	660	1940	1:1.9
A457 abs with Inaba 1569	240	1020	1:4.3
A457 abs with JS1569 WbeT	180	40	1.8:1
JS1569 WbeT	420	1580	1:3.8
WbeT abs with Ogawa A457	150	60	2.5:1
WbeT abs with	180	920	1:5.1

Inaba JS1569			
WbeT abs with JS1569 WbeT	120	100	1.2:1

Example 2: Genetically modified *Vibrio cholerae* cells expressing O1 antigens of both Ogawa and Inaba serotypes by expression of mutated *WbeT*-protein: Plasmid-based expression of mutated *WbeT*-protein

5 In a single entry in GenBank of the *wbeT* gene from a Hikojima strain there is a mutation converting a serine to proline at position 158 of the protein (S158P) although the same mutation has been described in a strain identified as being of the Inaba serotype (GenBank accession numbers FJ619106 and DQ401028 respectively). Having amplified the wild-type *wbeT* gene from the O1 El Tor Ogawa strain VX44945

10 with primers wbeT1 EcoRI (SEQ ID NO: 1 5'-CCCGGTCTCGAATTC CTGCATCTGCAAGTTGATTCTGTATG-3') and wbeT2 HindIII (SEQ ID NO: 2 5'-CCCGGTCTCAAGCTTATAGTGAACTCTTCGGAAATGTCTG-3'), it was digested with Eco31I and cloned into an expression vector derived from pAF1 () in which the cloned gene was placed under the control of the powerful synthetic tac promoter that had

15 been digested with EcoRI and HindIII. The sequence of the gene was confirmed by DNA sequencing of the plasmid with primers wbe1 (SEQ ID NO: 3 5'-CTGCATCTGCAAGTTGATTCTGTATG-3') and wbe2 (SEQ ID NO: 4 5'-ATAGTGAACTCTTCGGAAATGTCTG-3').

The DNA sequence of the wild-type *wbeT* gene is shown in SEQ ID NO: 5 whereas the

20 wild-type protein is shown in SEQ ID NO: 6.

The full sequence of the plasmid (pML-wbeTtac) expressing the wild-type *wbeT* is shown in SEQ ID NO: 7.

In order to construct the mutant library of *wbeT* carrying mutations at amino acid position 158 of the gene product, oligonucleotides wbeT m3 (SEQ ID NO: 8 5'-

GCGCGCCAGAACTTGGCTATTTTAAACC-3') and *wbeT* m1 (SEQ ID NO: 9 5'-GGGGGTTCGAAGTTTATGAGTTTGATAATAGGGTGNNBTCATTATATTTTCAAAAAAATACAGACATAGCAGATAAGGTTAAAAATAGCCAAGTTCTGGCGCGC-3') were synthesized. The two oligonucleotides were mixed in equimolar quantities and allowed to anneal at room temperature overnight. Full length double-stranded DNA was made by extension of the short *wbeT* m3 primer using T4 DNA polymerase in the presence of excess deoxyribonucleotide triphosphates. The resulting fragment was digested with Bsp119I and Van91I and ligated into pML-*wbeTtac* (SEQ ID NO: 7) digested with the same enzymes. The ligated DNA was used to transform commercially obtained electro-competent *E. coli* strain DH12S (Invitrogen). After incubation without antibiotic selection a small aliquot of the cells were spread onto a selective LB agar plate supplemented with ampicillin (100 µg/ml). The rest of the cells were diluted to 25 ml with fresh LB broth. Ampicillin was added to a final concentration of 100 µg/ml and the culture was grown overnight at 37° C in order to obtain a clone library. Aliquots of the resulting culture were supplemented with glycerol to a final concentration of 17% and stored at -70° C. Other aliquots were used to prepare plasmid DNA.

The colonies obtained on the LB agar plate were picked onto a fresh plate and colonies were cultured to prepare plasmid DNA. The plasmids were sequenced in order to determine whether the *wbeT* genes carried mutations. Mutants of *wbeT* obtained from the library are the following: S158G, S158P, S158V, S158I, S158L, S158A, S158T, S158M, S158W, S158R, S158C and S158F. Additionally the wild-type gene and a gene with the stop signal TGA at position 158 were isolated.

The different plasmids were isolated and used to transform the O1 classical Inaba strain JS1569. This strain has a mutant *wbeT* gene with the glycine (GGA) at position 219 of the protein being changed to a stop codon (TGA) resulting in a truncated and inactive product (SEQ ID NO: 10 and SEQ ID NO: 11).

There are other polymorphisms that do not appear to have any significance.

The different strains generated by the introduction of the different recombinant plasmids expressed different levels of the Ogawa antigen when grown under inducing conditions (in the presence of 1mM IPTG). The phenotype was assessed on the basis of agglutination assays and in some cases using inhibition ELISA (see Example 5 for description of materials and methods). The wild type gene gave rise to almost total serotype switching whereas others (such as S158P and S158G) gave slight but detectable agglutination with Ogawa-specific antiserum as well as agglutination with an Inaba-specific antiserum (and therefore conferred a Hikojima serotype). Some mutants had no detectable activity with Ogawa-specific antiserum (S158I and S158C) and yet others gave intermediate agglutination (S158T, S158F and S158W).

The results demonstrate unambiguously that mutations and specifically mutations at position 158 of the *wbeT* gene product result in proteins with altered enzyme activity. At present there is no reliable assay to directly quantitatively determine the levels of enzyme activity of these mutants compared to the wild-type, but the relevant end result can readily be evaluated as in Example 5. In summary, all except S158C and S158I were able to complement the Inaba phenotype of the host strain to some extent.

Example 3: Genetically modified *Vibrio cholerae* cells expressing O1 antigens of both Ogawa and Inaba serotypes by expression of mutated *WbeT*-protein:

Chromosomal insertion of mutant *wbeT*

The truncated chromosomal *wbeT* gene in the strain JS1569 was substituted with the mutant genes generated in example 2. The relevant mutated genes were amplified with primers *wbeT*1 BglII (SEQ ID NO: 1) and *wbeT*2 BglII (SEQ ID NO: 2). Amplified fragments were digested with BglII and ligated into the suicide vector pMT-SUICIDE (SEQ ID NO: 12) which had been digested with BamHI. This is a small R6K-based suicide vector constructed in this laboratory by M. Lebens which carries the chloramphenicol resistance gene and the origin of transfer (*oriT*) from the broad host-range plasmid RP4 that allows the plasmid to be conjugally transferred to *V.*

cholerae strain with the aid of a helper plasmid (pNJ5000; Grinter NJ, Gene. 1983 Jan-Feb;21(1-2):133-43).

In the clones that were generated, the *wbeT* genes (S158G and the wild-type) were both inserted with the cloned genes in the opposite orientation to the *cat* gene. The sequence of such vector is exemplified by SEQ ID NO: 13 (carrying wild-type *wbeT* gene; the construct for S158G is identical save for the nucleotides coding for *WbeT* residue 158).

The resulting plasmids were mated into strain JS1569 and selected on the basis of chloramphenicol and rifampicin resistance. Since the plasmid has no counter-selection for loss of the plasmid, its insertion into the chromosome by homologous recombination results in tandem copies of the *wbeT* gene separated by the plasmid. Depending upon where the recombination occurred, the clones had different phenotypes (see Example 5).

The strain that had received the wild-type gene (1342) had a clear Hikojima phenotype. Inhibition ELISA showed that it expressed only 15% of the Ogawa LPS present on the surface of the strain that that received the S158G mutant. The latter strain (1356) was in effect an Ogawa strain that agglutinated strongly with Ogawa-specific antiserum, but not at all with the Inaba-specific antiserum.

The strains were however very stable; they retained their LPS serotypes and remained chloramphenicol resistant even in the absence of selection, indicating that the plasmid was not readily lost.

PCR and sequencing using the *wbe1* and 2 primers (SEQ ID NO: 3 and 4, respectively) showed that there were two genes in the strains that varied at sites of variation between the gene present in the host and that which was introduced. Amplification and sequencing with primers *wbeT*for 87> (SEQ ID NO 14: 5'-CGGTGCAAACGTTGGAACCTTCTG-3') and *wbeT* rev 51< (SEQ ID NO 15: 5'-GGAAAACAATGCCATCCAAATTCGC-3') that only allow amplification if there are tandem copies of the *wbeT* gene successfully amplified the 3' end of the proximal

gene (from amino acid 87) and the 5' end of the distal gene up to amino acid 51 and the plasmid in between. Sequencing using the *wbeT*for 87> primer showed that in the strain 1342 the *wbeT* gene adjacent to the native promoter was the truncated host gene. The distal gene had the wild-type sequence but no promoter. This arrangement led to the Hikojima phenotype since the wild-type gene was being expressed at extremely low levels from a cryptic promoter.

In the Ogawa strain 1356 the arrangement was different. The recombination had resulted in the native *wbeT* gene being expressed from the native promoter and the mutant S158G gene being placed distally and therefore having no promoter recognizable at all. Both copies of the gene appear to have lost the stop codon at position 219, but this mutation had no apparent influence on the phenotype.

Example 4: Genetically modified *Vibrio cholerae* cells expressing O1 antigens of both Ogawa and Inaba serotypes by expressing low levels of native *WbeT*-protein

In conjunction with the experiments on mutant *wbeT* described in Example 2 it was noted that a control plasmid carrying the wild-type *wbeT* was able to partially complement the mutant gene in strain JS1569 even when it was not induced. This resulted in a Hikojima serotype even in the presence of the wild type gene demonstrating that the phenotype can also be achieved by limiting the levels of expression; in this case by keeping the *tac* promoter repressed and allowing only breakthrough expression that occurs in the absence of inducer.

In Example 3, the clone 1342 had a chromosomally integrated wild-type gene expressed from a cryptic promoter, which resulted in a Hikojima serotype. These results confirm that the expression of the wild-type gene at very low levels can result in the Hikojima serotype.

Example 5: Characterization of the phenotype of genetically modified *Vibrio cholerae* cells

V. cholerae bacteria of strain JS1569 (Inaba) that had been modified to contain plasmids encoding for either the wild-type *WbeT* methylase protein (strain

JS1569/S158S) or a mutated *wbeT* gene encoding for *WbeT* protein with a mutation in position 158 from S to G (JS1569/S158G) or from S to A (JS1569/S158A) were grown on LB agar plates, and single colonies were tested for agglutination by antibodies specific for Inaba and Ogawa O antigens, respectively.

- 5 These antibodies were obtained after first immunizing rabbits with purified Ogawa and Inaba LPS, respectively and then extensively absorbing the sera with formalin killed bacteria of the heterologous serotype in order to remove cross-reactive antibodies. After absorption, Ogawa-specific antiserum gave strong agglutination of reference *V. cholerae* cells of the Ogawa serotype but could not agglutinate Inaba
10 cells and *vice versa* for the Inaba specific serum .

Agglutination tests were performed by standard method. Briefly, a single colony from a fresh plate of the tested strain was suspended in 50-100 µl physiological saline buffer, and 10 µl of the suspension was placed on a microscope slide. Then 10 µl of appropriately diluted specific antiserum was added and mixed with the cells by tilting
15 the slide backwards and forwards for up to 5 minutes until agglutination was clearly visible. Each assay was compared with negative and positive controls consisting of cells from reference Inaba and Ogawa strains.

Additionally a control for spontaneous agglutination in which serum was replaced by buffer was performed for each strain tested. Results are shown in the table below
20 and show that the JS1569/S158S strain containing plasmid encoding for wild-type *WbeT* protein had completely switched in serotype from Inaba to Ogawa, the JS1569/S158G strain with a *WbeT* 158S to G mutation expressed strong Ogawa but also detectable Inaba reactivity, and JS1569/S158A with a *WbeT* 158S to A mutation had only marginal Ogawa reactivity.

Strain	<i>WbeT</i> encoding Plasmid	Agglutination with anti-Ogawa antibody	Agglutination with anti-Inaba antibody

JS1569 Inaba	None	-	+++
Cairo 50 Ogawa	None	+++	-
A457 Ogawa	None	+++	-
JS1569/S158S	WbeT S158S wild-type	+++	(+)
JS1569/S158G	WbeT S158G	++	++
JS1569/S158A	WbeT S158A	(+)	+++

These results were confirmed when formalin-killed bacteria of the same strains were tested for agglutination with the same sera. They were also confirmed and extended when the formalin-killed bacteria were tested for their quantitative expression of

5 Inaba and Ogawa antigens on the bacterial surface using an ELISA-inhibition method.

The method was performed as follows: High binding Greiner Bio-one plates were coated with Ogawa LPS by incubating overnight with 100 µl per well of a solution of 5 µg/ml purified Ogawa LPS in PBS. Starting with 200 microliter of OD₆₀₀ 1.00 formalin killed bacteria; seven serial five-fold dilutions were made (down to 1:15625) in PBS

10 with an eighth blank tube containing no cells. 150 microliter of each dilution was mixed together with an equal amount of appropriately diluted anti-Ogawa serum in PBS, 0.2% BSA. The samples were incubated at room temperature for 1 hour without shaking. The coated plates were washed twice with PBS and blocked with 200 µl/well of PBS, 0.1% BSA for 30 minutes at 37° C. The cells were removed from the

15 suspensions by centrifugation for 5 minutes at 20,000 x g and 100 microliter of the supernatants were added to the blocked the plate(s). A blank containing PBS, 0.1%

BSA with neither cells nor anti-Ogawa serum was included in all plates and all

samples were run in duplicate. Plates were incubated for 1 hour at room temperature and then washed three times with PBS, 0.05% Tween 20. 100 microliter of

20 appropriately diluted goat anti-rabbit IgG in PBS, 0.1% BSA, 0.05% Tween 20 was

added to each well and incubated for 1 hour at room temperature. The plate was washed three times with PBS, 0.05% Tween 20 before adding the substrate solution of 0.1% orthophenylenediamine (OPD) and 0.012% H₂O₂ in 0.1M citrate pH4.5. The absorbance was read at 490nm after 10min.

- 5 The bacterial dilution resulting in 50% inhibition was extrapolated and also the percentage inhibition of the absorbance at bacterial dilution of 1:25 with the results shown in the table below. The results show that the JS1569/S158S strain containing a *wbeT* gene encoding for wild-type *WbeT* could efficiently inhibit the specific anti-Ogawa serum, whereas the strains containing *wbeT* genes with single mutations
- 10 could also inhibit the anti-Ogawa serum with intermediate activity (JS1569/S158G) or just detectably (JS1569/S158A):

Strain	Dilution for 50% inhibition	% inhibition at dilution 1:25
JS1569 Inaba	<< 1:1	0
A457 Ogawa	1:60	65
JS1569/S158G	1:70	70
JS1569/S158S	1:1	20

- Based on the plasmids encoding for *WbeT* and S158G, respectively, two recombinant derivative strains of JS1569 , 1356 (wild-type *WbeT*) and 1342 (S158G *WbeT*) , were
- 15 obtained where the mutated *wbeT* gene had been stably inserted into the chromosome, giving unexpected but stable phenotypes. For an explanation and description of these strains see examples above. These strains and appropriate reference strains were subjected to colony blots for assaying Ogawa expression. Strains containing mutated *wbeT* genes were patched out on an LB agar plate
- 20 together with Inaba and Ogawa control strains and grown overnight at 37° C. A nitrocellulose membrane moistened with PBS was applied on the plate with the

grown out colonies and was left for 15 minutes at room temperature. The membrane was left to dry on a piece of paper for 5 minutes before it was blocked twice for 20 minutes in 10 ml of 1% Bovine serum albumin (BSA) in PBS at room temperature. The blocking liquid was discarded and replaced with an appropriate dilution of the anti-Ogawa serum in 10 ml in PBS containing 0.1% BSA and 0.05% Tween 20. The membrane was incubated at room temperature on a rocking table for 2 hours. The membrane was then washed three times with PBS containing 0.05% Tween20 before adding goat anti-rabbit IgG conjugated to horseradish peroxidase (Jackson Immunoresearch Laboratories Inc.) in 0.1% BSA in PBS with 0.05% Tween20 and incubating for 2 hours at room temperature with gentle agitation.

Following a further three washes in PSB, 0.05% Tween 20 and a single wash with PBS alone the membrane was developed for 15 minutes with 0.05% 4-chloro-1-naphtol and 0.015% H₂O₂ in 20 mM Tris -HCl pH 7.5 containing 500 mM NaCl and 16.7% methanol. It was then washed thoroughly with tap water and was left to dry on a piece of paper. A digital photo was taken of the developed membrane and the staining density measured with a computer system.

Results in the table show that strain 1356 expressed almost as much Ogawa antigen as the Ogawa reference strain whereas strain 1342 expressed substantially lesser amounts of Ogawa antigen. These findings were further confirmed when formalin-killed preparations of the strains were tested for quantitative expression of Ogawa antigen by inhibition-ELISA done as described above as also shown in the table:

Strain	Dot blot density units/mm ²	Dilution for 50% inhibition
A 457 Ogawa	12700	1:60
JS1569 Inaba	0	<<1:1
1356	10000	1:80
1342	4500	1:7

Example 6: Genetic modification of the endogenous *wbeT* gene to obtain Hikojima serotype

Although the strains presented in the above examples are stable and clearly have the desired phenotypes, an alternative manner of obtaining a Hikojima phenotype is to perform true gene substitutions in the endogenous gene. Suitable mutations (as disclosed above) at position 158 of the endogenous, active *wbeT* gene product also result in diminished activity and therefore a Hikojima serotype. This will result in a range of mutants with differing levels of Ogawa expression that can be tested for Hikojima expression as in Example 5 and in immunization experiments for the optimal immunogenic properties.

As mentioned, the pMT-SUICIDE vector lacks a suitable counter-selection gene and it has proved difficult isolate derivatives that have lost the plasmid and retain the desired gene and phenotype. For this reason a new suicide vector was constructed carrying the *sacB* gene from *Bacillus subtilis*, allowing strains that have lost the plasmid to be isolated by selection on plates containing sucrose since expression of the *sacB* gene product in gram-negative bacteria is lethal and only colonies derived from cells that have lost the plasmid due to homologous recombination between the two copies of the *wbeT* gene will survive. The plasmid, pMT Suicide/*sacB* (SEQ ID NO: 16) is much smaller than comparable plasmids with the same functions and is much easier to use.

The wild-type and a number of mutant *wbeT* genes have been cloned into the new vector and will be mated into the strain JS1569 as before, as well as to other strains such as a suitable Ogawa strain.

In order to optimize the chances of obtaining a correct clone the gene arrangement of the partial diploids that resulting from the transconjugation experiments will be analysed before a candidate strain is chosen for taking further for selection of strains that have recombined out the plasmid.

Example 7: Expression of hybrid CFA/I+CS2

It has recently been shown that *E. coli* TOP10 and *V. cholerae* JS1569 strains can express one of the major colonization factor of ETEC, i.e. CFA/I fimbriae, on their surface (Tobias J, Lebens M, Bölin I, Wiklund G, Svennerholm AM. Vaccine. 2008 Feb 6;26(6):743-52). Following electroporation of a CFA/I-containing expression vector
5 into the above strains, the surface expression was detected by dot blot assay.

It has also recently been shown that *E. coli* TOP10 is capable of expressing a hybrid fimbriae containing the major subunits of both CFA/I and CS2- i.e. an additional major colonization factor of ETEC (Tobias J, Svennerholm AM, Holmgren J, Lebens M. Appl Microbiol Biotechnol. 2010 Jul;87(4))

10 Therefore, we examined the feasibility of expression of the same hybrid fimbriae on *V. cholerae* JS1569. The strain was electroporated with the expression vector pJT-CFA/I-CotA as described (Tobias et al. 2008, *supra*; Tobias J, Holmgren J, Hellman M, Nygren E, Lebens M, Svennerholm AM. Vaccine. 2010 Aug 20. [Epub ahead of print])

Fifty colonies (clones) were then streaked on two LB plates supplemented with
15 chloramphenicol (12.5 µg/ml) and IPTG (1 mM), followed by over-night incubation at 37°C. Specific monoclonal antibodies (MAb) 1:6 against CFA/I and MAb 10:3 against CS2 were then applied in colony blot assay (Tobias et al, 2010, *supra*) to examine the surface expression of the hybrid CFA/I-CotA fimbriae on *V. cholerae* JS1569. The blots were then developed and showed positive signal of surface expression of the hybrid
20 CFA/I-CS2 fimbriae on all tested fifty clones of *V. cholerae* JS1569.

Thus it is possible to combine the expression of antigenic hybrid fimbriae in the same cells that have been engineered to express O1 antigens of both Ogawa and Inaba serotypes.

CLAIMS:

1. A vaccine comprising *Vibrio cholerae* O1 cells, wherein said cells comprise O1 antigens of both Ogawa and Inaba serotypes, and said cells are inactivated or killed cells.
2. A vaccine according to claim 1, wherein the vaccine comprises multiple *Vibrio cholerae* O1 cells that comprise O1 antigens of both Ogawa and Inaba serotypes, and wherein on average, 10-90 % of the O1 antigens of the cells are of the Ogawa-serotype.
3. A vaccine according to claim 1 or 2, wherein the cell further comprises one or more ETEC colonization factor (CF) protein(s), wherein said CF protein(s) is/are expressed either as single, double or hybrid fimbriae.
4. A vaccine according to claim 3, wherein the one or more CF protein(s) is/are CFA/I, CS2, CS5, or any combination thereof.
5. A vaccine according to any one of claims 1-4, with the proviso that said vaccine does not contain any further immunologically active whole cells in addition to the *Vibrio cholerae* O1 cells that comprise O1 antigens of both Ogawa and Inaba serotypes.
6. A vaccine according to any one of claims 1-5, wherein the vaccine is formulated for oral administration.
7. A vaccine according to any one of claims 1-6, wherein the cell is formalin-inactivated.

8. A vaccine according to any one of claims 1-7, wherein the vaccine is formulated for use in preventive immunization against cholera, enterotoxigenic *Escherichia coli*-infection (ETEC), or both.
9. Use of a vaccine according to any one of claims 1-8 for inducing preventive immunity in a subject, wherein the preventive immunity is against cholera, enterotoxigenic *Escherichia coli*-infection (ETEC), or both.
10. A use according to claim 9, wherein the vaccine is formulated for oral administration.
11. A DNA-construct comprising:

DNA coding for a *WbeT*-protein having at least 70 % sequence identity to SEQ ID NO: 6 operatively coupled to a promoter for inducing protein expression in a *Vibrio cholerae* O1 host cell,

wherein the coded *WbeT*-protein comprises sequence modifications in relation to SEQ ID NO: 6 that reduce the enzymatic activity of the coded protein relative to the enzymatic activity of a protein with a sequence identical to SEQ ID NO: 6,

wherein the sequence modifications comprise a substitution of the serine residue in position 158 of SEQ ID NO: 6.
12. A DNA-construct according to claim 11, wherein the sequence modifications comprise a substitution of the serine residue in position 158 of SEQ ID NO: 6 to glycine, proline, threonine, phenylalanine or tryptophan.

13. A DNA-construct comprising:

DNA coding for a *WbeT*-protein having at least 70 % sequence identity to SEQ ID NO: 6 operatively coupled to a promoter for inducing protein expression in a *Vibrio cholerae* O1 host cell,

wherein the promoter is for inducing the expression of the coded *WbeT*-protein in a *Vibrio cholerae* O1 host cell initially of Inaba phenotype to such level of transgenic *WbeT* protein expression as to allow simultaneous expression of both Inaba and Ogawa antigens by the host cell,

wherein the coded *WbeT*-protein comprises a substitution of the serine residue in position 158 of SEQ ID NO: 6.

14. A DNA-construct according to any one of claims 11-13, wherein the promoter is an inducible promoter, wherein the inducible promoter is a *tac* or *lac* promoter.

15. A DNA-construct according to any one of claims 11-14, wherein the DNA construct is a plasmid vector for replication in a host cell or a vector that performs chromosomal integration in a host cell.

16. A DNA-construct according to any one of claims 11-15, further comprising a selectable marker.

17. A DNA construct according to any one of claims 11-15 for homologous recombination in a *Vibrio Cholerae* O1 host cell, wherein the construct is adapted to modify the endogenous *wbeT* gene of the host by means of homologous recombination.

18. A DNA construct according to claim 17, further comprising a selectable marker.
19. A *Vibrio cholerae* O1 cell simultaneously expressing both Inaba and Ogawa O1 antigens, wherein
 - a. the endogenous *wbeT*-gene of the cell or the protein coded thereof is inactive;
 - b. the cell comprises a recombinant DNA-construct inducing expression of *WbeT* enzyme activity; and wherein said recombinant DNA-construct is a DNA construct according to any one of claims 11-18; and
 - c. the level of transgenic *WbeT* enzyme activity is such that the cell simultaneously expresses Inaba and Ogawa O1 antigens.
20. A *Vibrio cholerae* O1 cell according to claim 19 wherein the recombinant DNA-construct is a DNA construct according to any one of claims 11-18.
21. An isolated *Vibrio cholerae* O1 cell simultaneously expressing both Inaba and Ogawa O1 antigens wherein
 - a. the cell comprises an endogenous *wbeT*-gene; and
 - b. the cell comprises a recombinant DNA-construct for modulation of the expression level of endogenous *wbeT* gene or the enzymatic activity of the product thereof; and wherein
 - c. the modulated level of *WbeT* enzyme activity is such that the cell simultaneously expresses Inaba and Ogawa O1 antigens,wherein 10-90% of the O1 antigen expressed by the cell is of the Ogawa-serotype.

22. A *Vibrio cholerae* O1 cell according to claim 21 wherein the recombinant DNA-construct is a DNA construct according to claim 17 or 18.
23. A *Vibrio cholerae* O1 cell according to any one of claims 19-21, wherein the cell further express one or more ETEC colonization factor (CF) protein(s), wherein said CF protein(s) is/are expressed either as single, double or hybrid fimbriae.
24. A *Vibrio cholerae* O1 cell according to claim 23 wherein the one or more CF protein(s) is/are CFA/I, CS2, CS5 or any combination thereof.
25. A vaccine according to any one of claims 1-7, wherein the cell is a cell according to any one of claims 19-24 which has been inactivated or killed.
26. A method for manufacturing a vaccine, comprising the steps of:
- a. providing a *Vibrio cholerae* O1 cell comprising O1 antigens of both Ogawa and Inaba serotypes; and
 - b. killing said cell.
27. A method according to claim 26, wherein the killing is performed by formalin-treatment.
28. A method according to claim 26 or 27 wherein the cell is a cell according to any one of claims 19-23.